Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Региональная программа лечения больных первично-генерализованным и метастатическим раком молочной железы
Региональная программа лечения больных первично-генерализованным и метастатическим раком молочной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Cameron RB. Malignancies of the Breast. Chap. 53 in A Lange Clinical Manual - Practical Oncology 1st Edition. Norwalk: Appleton & Lange, 1994.
2. Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
3. Norton L, Hortobagyi GN, Shpall EJ. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
4. Papahadjopoulous D, Allen TN, Gabizon A., et-al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.
5. Martin FJ, Gabizon A, Human Pharmacokinetics of Stealth Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
6. Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
7. Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12-15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
8. O'Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) vs conventional doxorubicin for first-line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9
9. S-E Al-Batran et al.The clinical benefit of pegilated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br Jour Cancer, (2006), 1–6
10. D.Lorusso et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), review article, Annals Oncol, Jan 17, 2007:1–6.
2. Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
3. Norton L, Hortobagyi GN, Shpall EJ. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
4. Papahadjopoulous D, Allen TN, Gabizon A., et-al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.
5. Martin FJ, Gabizon A, Human Pharmacokinetics of Stealth Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
6. Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
7. Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12-15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
8. O'Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) vs conventional doxorubicin for first-line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9
9. S-E Al-Batran et al.The clinical benefit of pegilated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br Jour Cancer, (2006), 1–6
10. D.Lorusso et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), review article, Annals Oncol, Jan 17, 2007:1–6.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.